MARKET

TXMD

TXMD

TherapeuticsMD
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.280
+0.090
+7.56%
Pre Market: 1.230 -0.05 -3.91% 08:43 05/06 EDT
OPEN
1.210
PREV CLOSE
1.190
HIGH
1.290
LOW
1.170
VOLUME
22.66K
TURNOVER
--
52 WEEK HIGH
2.750
52 WEEK LOW
1.050
MARKET CAP
503.28M
P/E (TTM)
-1.9188
1D
5D
1M
3M
1Y
5Y
TherapeuticsMD drops 3% despite consensus beating Q1 results
TherapeuticsMD (TXMD) reports financial results for the first quarter ended March 31, 2021.Total revenue for Q1 increased 62% to $19.87M compared to Q1 2020. Analysts forecast was $19.77M.ANNOVERA net product
Seekingalpha · 16m ago
BRIEF-Therapeuticsmd Reports Q1 Revenue $19.9 mln
reuters.com · 1h ago
TherapeuticsMD Q1 EPS $(0.11) Beats $(0.12) Estimate, Sales $19.90M Beat $19.77M Estimate
TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 47.62 percent increase over losses of $(0.21) per share from the
Benzinga · 1h ago
Therapeutics MD EPS beats by $0.01, beats on revenue
Therapeutics MD (TXMD): Q1 GAAP EPS of -$0.11 beats by $0.01.Revenue of $19.87M (+62.2% Y/Y) beats by $0.1M.Improved average net revenue per unit for IMVEXXY to $61 and BIJUVA to $69.Shares -5.5%
Seekingalpha · 1h ago
TherapeuticsMD Announces First Quarter 2021 Financial Results
TherapeuticsMD announces business and financial results for Q1 2021; increases gained in net revenue and net product revenue.
Business Wire · 1h ago
TherapeuticsMD, Inc. to Host Earnings Call
May 06, 2021 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / May 6, 2021 / TherapeuticsMD, Inc. (NASDAQ:TXMD) will be discussing their earnings...
ACCESSWIRE · 1h ago
Earnings Scheduled For May 6, 2021
  Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.
Benzinga · 4h ago
-- Earnings Flash (TXMD) THERAPEUTICSMD Reports Q1 Loss $-0.11, vs. Street Est of $-0.12
MT Newswires · 5h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TXMD. Analyze the recent business situations of TherapeuticsMD through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TXMD stock price target is 6.17 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 253
Institutional Holdings: 178.44M
% Owned: 45.38%
Shares Outstanding: 393.19M
TypeInstitutionsShares
Increased
45
18.99M
New
30
12.60M
Decreased
39
25.30M
Sold Out
12
2.65M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.68%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Chairman/Independent Director
Tommy Thompson
President/Secretary
John Milligan
Chief Executive Officer/Director
Robert Finizio
Co-Founder
Brian Bernick
Chief Financial Officer
James D'Arecca
Chief Information Officer
Adam Miller
Chief Compliance Officer
John Knighton
Vice President - Finance
Michael Donegan
General Counsel
Marlan Walker
Other
Dawn Halkuff
Other
Mitchell Krassan
Other
Sebastian Mirkin
Other
Bharat Warrier
Independent Director
Paul Bisaro
Independent Director
J. Martin Carroll
Independent Director
Cooper Collins
Independent Director
Karen Ling
Independent Director
Jules Musing
Independent Director
Gail Naughton
Independent Director
Angus Russell
No Data
About TXMD
TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Webull offers kinds of TherapeuticsMD Inc stock information, including NASDAQ:TXMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TXMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TXMD stock methods without spending real money on the virtual paper trading platform.